Purpose/objectives: To conduct a role delineation study of basic oncology nursing practice as a basis for revision of the blueprint for the Oncology Certified Nurse (OCN) examination.
Design: Three-phase study of oncology nurses' practice.
Sample: 735 oncology nurses randomly chosen from all nurses who are OCN certified.
Methods: A pilot survey was mailed to a small group to allow refinement of the survey instrument. The revised survey then was e-mailed to a total sample of 3,000 OCNs. The results and input from experts on the subject matter were used to revise the test blueprint.
Main Research Variables: Frequency and importance of 223 oncology nursing activities previously identified by the group of experts in oncology nursing.
Findings: The highest ranked items for the combined frequency and importance scales pertained to the subscales Professional Performance, Patient/Family Education, Comfort, Protective Mechanisms, and Coping. The lowest ranked activities pertained to subscales Research, Detection, Sexuality, and Prevention.
Conclusions: The blueprint for the OCN examination reflects entry-level oncology nursing practice and includes eight domains of practice: Quality of Life (36%), Protective Mechanisms (13%), Gastrointestinal and Urinary Function (10%), Cardiopulmonary Function (8%), Oncologic Emergencies (7%), Scientific Basis for Practice (12%), Health Promotion (3%), and Professional Performance (11%).
Implications For Nursing: Because oncology nursing is changing, reconfirming and updating the blueprint for the certification examination is necessary. Certification examinations beginning in April 2003 will be based on the revised blueprint.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1188/02.ONF.E110-E117 | DOI Listing |
Dig Dis Sci
January 2025
INFINY Institute, Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Université de Lorraine, 54500 , Vandœuvre-lès-Nancy, France.
Background: Therapeutic drug monitoring is important for optimizing anti-tumor necrosis factor-α (TNF-α) therapy in inflammatory bowel disease. However, the exposure-response relationship has never been assessed in pouchitis.
Aims: To explore associations between anti-TNF-α drug concentration and pouchitis disease activity in patients with a background of ulcerative colitis.
iScience
January 2025
Department of Adult Health Nursing, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Comprehensive data on the epidemiology of cancer-related thrombosis in Africa has been sparse until recently. Thus, this review was aimed to investigate the magnitude of cancer-related thrombosis in Africa. To obtain key articles, comprehensive search was conducted using various databases.
View Article and Find Full Text PDFCurr Pharm Des
January 2025
Department of Radiopharmacy, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Introduction: Most Breast Cancer (BC) patients undergoing Radiotherapy (RT) are potentially susceptible to skin toxicity and prone to clinical symptom complaints. This study aimed to investigate the effect of oral Atorvastatin (ATV) administration on skin toxicity in BC patients undergoing RT.
Methods: One hundred BC patients were randomly assigned to oral ATV (40 mg) or placebo tablets two days before beginning the RT until the eighth week of the RT regimen was completed.
JMIR Pediatr Parent
January 2025
Department of Sport Science and Physical Activity, Taibah University, Medina, Saudi Arabia.
Background: Obesity rates among Saudi adolescents are increasing, with regional variations highlighting the need for tailored interventions. School-based health programs in Saudi Arabia are limited and often emphasize weight and body size, potentially exacerbating body image dissatisfaction. There is limited knowledge on the feasibility of non-weight-centric educational programs in Saudi Arabia and their effects on health behaviors and body image.
View Article and Find Full Text PDFFuture Oncol
January 2025
School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Background: The accessibility and outcomes of cyclin-dependent kinase 4 and 6 inhibitors (CDKi) in metastatic breast cancer (MBC) according to demographic factors are unknown.
Research Design And Methods: Retrospective review of patients with ER+ MBC prescribed first-line CDKi therapy from January 2015 through December 2022. Abstraction included time from CDKi prescription to drug initiation (TTI), time from CDKi initiation to progression (TTP), time from CDKi initiation to death or 6/30/2022, and variables (age, race, partner status, insurance type, BMI, number of comorbidities).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!